Ketoprofen as an good friend of the rheumatologist Review article
Article Sidebar
Published:
Dec 31, 2014
Keywords:
ketoprofen, individual risk factors
Main Article Content
Abstract
Successful treatment of pain and arthritis in the course of osteoarthritis or systemic connective tissue diseases is possible with classical non-steroidal anti-inflammatory drug – ketoprofen. To make the ketoprofen treatment safe, individual risk factors should be taken into consideration.
Article Details
How to Cite
Rupiński , R. (2014). Ketoprofen as an good friend of the rheumatologist. Medycyna Faktow (J EBM), 7(4(25), 75-75. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2340
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Ketoprofen. Opis substancji.
2. Tłustochowicz W.: Zalecenia postępowania w roku 2014 – choroba zwyrodnieniowa stawów. Medycyna Faktów 2014; 2(23).
3. Scheiman J.M., Hindley C.E.: Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin. Ther. 2010; 32.
4. Dobrogowski J., Istrati J., Woroń J.: Postępowanie farmakologiczne w chorobie zwyrodnieniowej stawów. PZWL, Warszawa 2013.
5. Gigante A., Tagarro I.: Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole. Clin. Drug. Investig. 2012; 32(4).
6. Wanders A., Heijde Dv., Landewé R. et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005; 52(6).
7. Altman R.D., Honig S., Levin J.M. et al.: Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J. Rheumatol. 1988; 15(9).
8. Castellsague J., Riera-Guardia N., Calingaert B. et al.: Individual NSAIDs and Upper Gastrointestinal Complications – A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project). Drug Saf. 2012; 35(12).
9. Tielemans M.M., Eikendal T., Jansen J.B. et al.: Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf. 2010; 33(6).
10. Lanza F.L., Chan F.K., Quigley E.M.: Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterol. 2009; 104(3).
11. Hohlfeld T., Saxena A., Schror K.: High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs – pharmacological mechanisms and clinical relevance. Thromb. Haemost. 2013; 109.
12. Gargiulo G., Capodanno D., Longo G. et al.: Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Rev. Cardiovasc. Ther. 2014; 12(10).
13. Lindhardsen J. et al.: Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann. Rheum. Dis. 2014; 73.
14. Crofford L.J.: Use of NSAIDs in treating patients with arthritis. Arthritis Research & Therapy 2013; 15(supl. 3).
2. Tłustochowicz W.: Zalecenia postępowania w roku 2014 – choroba zwyrodnieniowa stawów. Medycyna Faktów 2014; 2(23).
3. Scheiman J.M., Hindley C.E.: Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin. Ther. 2010; 32.
4. Dobrogowski J., Istrati J., Woroń J.: Postępowanie farmakologiczne w chorobie zwyrodnieniowej stawów. PZWL, Warszawa 2013.
5. Gigante A., Tagarro I.: Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole. Clin. Drug. Investig. 2012; 32(4).
6. Wanders A., Heijde Dv., Landewé R. et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005; 52(6).
7. Altman R.D., Honig S., Levin J.M. et al.: Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J. Rheumatol. 1988; 15(9).
8. Castellsague J., Riera-Guardia N., Calingaert B. et al.: Individual NSAIDs and Upper Gastrointestinal Complications – A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project). Drug Saf. 2012; 35(12).
9. Tielemans M.M., Eikendal T., Jansen J.B. et al.: Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf. 2010; 33(6).
10. Lanza F.L., Chan F.K., Quigley E.M.: Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterol. 2009; 104(3).
11. Hohlfeld T., Saxena A., Schror K.: High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs – pharmacological mechanisms and clinical relevance. Thromb. Haemost. 2013; 109.
12. Gargiulo G., Capodanno D., Longo G. et al.: Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes. Expert Rev. Cardiovasc. Ther. 2014; 12(10).
13. Lindhardsen J. et al.: Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann. Rheum. Dis. 2014; 73.
14. Crofford L.J.: Use of NSAIDs in treating patients with arthritis. Arthritis Research & Therapy 2013; 15(supl. 3).